Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (3089)	8/16/1999 10:42:00 PM
From: Bill Wexler	Read Replies (1) \| Respond to of 10293

The REFR shills have now progressed to the "shorting is un-american" phase... post.messages.yahoo.com I figure that we are at or past the apex of this latest pump. As Mr. P!nk would say..."short with impunity!"

To: Bill Wexler who wrote (3089)	8/16/1999 10:59:00 PM
From: pz	Read Replies (1) \| Respond to of 10293

Bill, <<<The GUMM stock fraud announces increased losses and negligible sales of the ineffective quack medication Zicam:>>> I want to buy some cheap shares of GUMM tomorrow, so could you please work a little harder at driving down the price? Thanks in advance for all of your help on this. Paul

To: Bill Wexler who wrote (3089)	8/16/1999 11:17:00 PM
From: DanZ	Read Replies (1) \| Respond to of 10293

Bill, You failed to mention that sales of Zicam in Q2 were expected to be lower than in Q1. The company began shipping Zicam to new retailers such as Walmart, Target, and Rite Aid in the third quarter and those sales are not reflected in Q2. In addition, GumTech virtually stopped advertising in the second quarter because they didn't have full distribution and the summer isn't exactly during the cold season. Second quarter sales of Zicam reflect reorders from a limited existing retail base and met expectations. You also failed to mention that GumTech's gross margins improved substantially in Q2 and that their operating expenses as a percentage of sales declined. This is quite an accomplishment given that one might expect lower efficiencies with sales lower than Q1 99. The company's gross profit margin on gum was higher than any quarter since 1997. I didn't expect sales of gum products to be lower in Q2 than Q1 but I don't see this as a big negative because GumTech isn't going to get rich on Breath Asure Dental Gum, Ranir dental gums, Acutrim Diet Gum, and other current gum products. The stock partially reflects future sales of nicotine gum, a dental gum contract with a major oral health care provider, and sales of Zicam in the next two quarters. You would have more credibility if you acknowledge more than just what you perceive to be negative aspects of a report. As I have said before, the market won't ignore things just because you choose to sweep them under the rug. I'm still waiting for an answer to a question in my last post to you. Why is it so hard for you to answer a question about something that you stated? I guess it's just part of your personality to ignore things that you don't want to discuss. Dan